SuperworthAnavex Life Sciences market cap AVXL
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $123.3M
- Highest close in our data
- $1.8B
- Jul 2021
Anavex Life Sciences is worth $123.3M at the close on Oct 23, 2026, at $1.33 a share.
That is down 83% over the last year and down 91% over five years.
Its highest close in our data was $1.8B in Jul 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $123.3M | $121.4M | $470M | −62% |
| 2025 | $325.2M | $280M | $1B | −68% |
| 2024 | $1B | $282.5M | $1B | +34% |
| 2023 | $764.2M | $426.1M | $877.9M | +6% |
| 2022 | $721.9M | $596.4M | $1.2B | −45% |
| 2021 | $1.3B | $377.7M | $1.8B | +265% |
| 2020 | $361.6M | $142.6M | $364.2M | +154% |
| 2019 | $142.6M | $84.8M | $185.9M | +101% |
| 2018 | $70.8M | $65.7M | $186.7M | −50% |
| 2017 | $142.4M | $139.3M | $254M | −9% |
| 2016 | $156.9M | $89.6M | $270.7M | −19% |
| 2015 | $192.7M | $8.9M | $318.6M | +2623% |
| 2014 | $7.1M | $6.6M | $17.5M | −24% |
| 2013 | $9.3M | $9.3M | $28.3M | −61% |
| 2012 | $23.6M | $16.5M | $53.6M | −29% |
| 2011 | $33.2M | $31.4M | $60.1M | n/a |
Against its peers
Companies in Healthcare nearest Anavex Life Sciences' size, closest first, today.
| Company | Market cap |
|---|---|
| AVXLAnavex Life Sciences | $123.3M |
| KEQUKewaunee Scientific | $94.9M |
| ICCCImmucell | $93.1M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| LFVNLifevantage | $73.4M |
| NATRNatures Sunshine Products | $213.8M |
| ELMDElectromed | $220.6M |
| SPROSpero Therapeutics | $64.6M |
| UTMDUtah Medical Products | $236.3M |
| APTAlpha Pro Tech | $56.7M |
| Peer median | $147.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Anavex Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.